The present invention relates to diazole derivatives of the general formula (I) wherein A, E, R¹, Wand R³ are as defined in the claims and description, their use for the preparation of medicaments for treating diseases and processes for preparing them.
Title: PYRIDIN-4-YL-ETHYNYLIMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS

Abstract: The present invention relates to diazole derivatives of the general formula (I) wherein A, E, R², and Wand R³ are as defined in the claims and description, their use for the preparation of medicaments for treating diseases and processes for preparing them.
The present invention relates to diazole derivatives of the general formula

![Chemical Structure](image)

wherein

- $\text{one of } A \text{ or } B \text{ is } N \text{ and the other is } C$;
- $R^1$ is halogen or cyano;
- $R^2$ is lower alkyl;
- $R^3$ is aryl or heteroaryl, which are optionally substituted by:
  - one, two or three substituents, selected from the group consisting of halogen,
  - lower alkyl, lower alkoxy, cycloalkyl, lower haloalkyl, lower haloalkoxy, cyano,
  - $NR'R''$ or by
  - 1-morpholiny1, or by
  - 1-pyrrolidinyl, optionally substituted by $(CH_2)_n OR$, or by
  - piperidinyl, optionally substituted by $(CH_2)_n OR$, or by
  - 1,1-dioxo-thiomorpholiny1 or by
  - piperaziny1, optionally substituted by lower alkyl or $(CH_2)_n$-cycloalkyl;
- $R$ is hydrogen, lower alkyl or $(CH_2)_n$-cycloalkyl;
- $R', R''$ are independently from each other hydrogen, lower alkyl, $(CH_2)_n$-cycloalkyl or $(CH_2)_n OR$;
- $n$ is 1 or 2;
- $R^4$ is $CF_2$, $C_3$, or $C(O)H$, $CH_2 R^5$ wherein $R^5$ is hydrogen, $OH$, $C_1-C_6$-alkyl or $C_3-C_{12}$-cycloalkyl;
- as well as to pharmaceutically acceptable salts thereof.
It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists. Compounds of formula I are distinguished by having valuable therapeutic properties. They can be used in the treatment or prevention of mGluR5 receptor mediated disorders.

In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.

Glutamate is the major excitatory neurotransmitter in the brain and plays a unique role in a variety of central nervous system (CNS) functions. The glutamate-dependent stimulus receptors are divided into two main groups. The first main group, namely the ionotropic receptors, forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein coupled receptors.

At present, eight different members of these mGluR are known and of these some even have sub-types. According to their sequence homology, signal transduction mechanisms and agonist selectivity, these eight receptors can be sub-divided into three sub-groups:

mGluR1 and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR6, mGluR7 and mGluR8 belong to group III.

Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.

Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are ischemia, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate addiction, anxiety, vomiting, dyskinesia and depressions.
Disorders mediated full or in part by mGluR5 are for example acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency (Expert Opin. Ther. Patents (2002), 12, (12)).

Selective mGluR5 antagonists are especially useful for the treatment of anxiety and pain.

The invention relates to compounds of formula I and their pharmaceutically acceptable salts, to the above-mentioned compounds as pharmaceutically active substances and their production.

The invention also relates to a process for preparing a compound according to general formula I following the general procedures as outlined above for compounds of formula I.

Moreover the invention relates also to medicaments containing one or more compounds of the present invention and pharmaceutically acceptable excipients for the treatment and prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorders, in particular anxiety and chronic or acute pain, protection against liver damage or failure whether drug or disease induced.

The invention also relates to the use of a compound in accordance with the present invention as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and prevention of mGluR5 receptor mediated disorders as outlined above.

The following definitions of general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.

The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and the like.

The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bound via an oxygen atom. Examples of "lower alkoxy" residues include methoxy, ethoxy, isopropoxy and the like.

The term "halogen" denotes fluorine, chlorine, bromine and iodine.
"lower haloalkoxy" denotes lower alkoxy group as defined above which is
substituted by one or more halogen. Examples of lower haloalkoxy include but are not
limited to methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as
those groups specifically illustrated by the examples herein below. Preferred lower
haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.

"lower haloalkyl" denotes a lower alkyl group as defined above which is substituted
by one or more halogen. Examples of lower haloalkyl include but are not limited to
methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl
substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically
illustrated by the examples herein below. Preferred lower haloalkyl are difluoro- or
trifluoro-methyl or ethyl.

"Aryl" represents an aromatic carbocyclic group consisting of one individual ring,
or one or more fused rings in which at least one ring is aromatic in nature. Preferred aryl
group is phenyl.

The term "heteroaryl" refers to an aromatic 5- or 6-membered ring containing one
or more heteroatoms selected from nitrogen, oxygen or sulphur. Preferred are those
heteroaryl groups selected from nitrogen. Examples of such heteroaryl groups are
pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl.

The term "cycloalkyl" denotes a saturated carbocyclic group, containing 3 – 12
carbon atoms, preferably 3-6 carbon atoms.

The term "pharmaceutically acceptable salt" refers to any salt derived from an
inorganic or organic acid or base. Such salts include: acid addition salts formed with
inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid; or formed with organic acids such as acetic acid, benzenesulfonic acid,
benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid,
glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphtoic acid, 2-
hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic
acid, methanesulfonic acid, muconic acid, 2-naphthalesulfonic acid, propionic acid,
salicic acid, succinic acid, tartaric acid, p-toluenesulfonic acid or trimethylacetic acid.

Preferred compounds of formula I are those compounds of formulae Ia and Ib:
wherein $R^1$, $R^2$, $R^3$ and $R^4$ are as defined herein above.

In the compounds of formulae I, Ia or Ib, according to the invention, preferred $R^1$ is halogen and preferably chloro or cyano.

Preferred $R^2$ is methyl or i-propyl.

Preferred $R^3$ is selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl which may be substituted by one or more chloro, fluoro, lower alkyl, lower alkoxy, cyano, lower haloalkyl, lower haloalkoxy or cycloalkyl.

Preferred $R^4$ is lower alkyl, CHF$_2$ or CH$_2$OH and preferably methyl.

Preferred compounds are those compounds of formulae Ia and Ib wherein:

- $R^1$ is halogen and preferably chloro or cyano;
- $R^2$ is methyl or i-propyl;
- $R^3$ is selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl which may be substituted by one or more chloro, fluoro, lower alkyl, lower alkoxy, cyano, lower haloalkyl, lower haloalkoxy or cycloalkyl; and
- $R^4$ is CHF$_2$, CH$_2$R$^5$ wherein $R^5$ is hydrogen, OH or C$_1$-C$_6$-alkyl and preferably $R^4$ is methyl;
- and pharmaceutically acceptable salts thereof.
Preferred are those compounds of formula Ia, wherein, R³ is unsubstituted or substituted heteroaryl, wherein the substitution is selected from chloro, fluoro, CF₃, and lower alkyl, for example the following compounds:

2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-methyl-pyridine;
2-Chloro-5-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-4-trifluoromethyl-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyrazine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-(trifluoromethyl)-pyridine; and
3-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-fluoro-pyridine.

Especially preferred are further those compounds of formula Ia, wherein, R³ is aryl, substituted by one or more chloro, fluoro, CF₃, and lower alkyl, lower alkoxy, CF₃O, 1-morpholinyl, for example the following compounds:

2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(2,4-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3,5-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-fluoro-2-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-fluoro-3-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-(2,5-dimethyl-1-p-tolyl-1H-imidazol-4-ylethynyl)-pyridine;
2-Chloro-4-[1-(3-chloro-4-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-fluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(4-chloro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-2-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(2-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[5-difluoromethyl-1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylyethynyl]-pyridine;
[5-(2-Chloro-pyridin-4-ylyethynyl)-3-(4-fluoro-phenyl)-2-methyl-3H-imidazol-4-yl]-methanol;
2-Chloro-4-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3,5-difluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(4-methoxy-3-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
4-[3-(4-(2-Chloro-pyridin-4-ylyethynyl)-2,5-dimethyl-imidazol-1-yl]-5-fluoro-phenyl]-morpholine;
2-Chloro-4-[1-(4-fluoro-2-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(2-fluoro-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-methyl-3-trifluoromethyl-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethyl-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-5-trifluoromethyl-phenyl)-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-5-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-4-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3,5-dichloro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
5
2-Chloro-4-[1-(3-fluoro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine; and
10
2-Chloro-4-[1-(3-fluoro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylyethynyl]-pyridine.

Still other preferred are further those compounds of formula Ib, wherein R³ is aryl, substituted by one or more fluoro, especially the following compound: 2-Chloro-4-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-ylyethynyl]-pyridine.

The compounds of formula Ia of the invention may be prepared according to various processes.

In an embodiment, the process of the invention comprises the following steps of reacting a compound of formula II

![Diagram](II)

with a compound of formula III

![Diagram](III)

in order to obtain the compound of formula Ia;
wherein R¹, R², R³ and R⁴ are as defined above and X is halogen, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

This process is described in more detail in scheme 1 and general procedure 1.

In another embodiment, the compounds of formula Ia may be prepared according to the following process of the invention which comprises the step of reacting a compound of formula IV
with a compound of formula V

\[
\begin{array}{c}
\text{Y} \\
\text{R}^1 \\
\text{V}
\end{array}
\]

in order to obtain the compound of formula Ia;

wherein \( R^1, R^2, R^3 \) and \( R^4 \) are as defined above and \( X \) is halogen, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. This process is described in more detail in scheme 2 and general procedure 2.

In still another embodiment, the compounds of formula Ia may be prepared according to the following process of the invention which comprises the step of reacting a compound of formula Ic

\[
\begin{array}{c}
\text{X} \\
\text{R}^1 \\
\text{N} \\
\text{R}^2 \\
\text{N} \\
\text{R}^3 \\
\text{Ic}
\end{array}
\]

with a compound of formula VI

\[
\begin{array}{c}
\text{R}^4-X \\
\text{VI}
\end{array}
\]

in order to obtain the compound of formula Ia;

wherein \( R^1, R^2, R^3 \) and \( R^4 \) are as defined above and \( X \) is halogen, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. This process is described in more detail in scheme 3 and general procedure 3.

The compounds of formula Ib may be prepared according to the following process of the invention which comprises the step of reacting a compound of formula XXVI

\[
\begin{array}{c}
\text{XXVI} \\
\text{R}^2 \\
\text{R}^3 \\
\text{N} \\
\text{R}^4 \\
\text{O}
\end{array}
\]

with a compound of formula XXVII

\[
\begin{array}{c}
\text{XXVII}
\end{array}
\]
in order to obtain a compound of formula XXVIII

and convert the compound of formula XXVIII into the compound of formula 1b;

wherein $R^1$, $R^2$, $R^3$ and $R^4$ are as defined above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. This process is described in more detail in scheme 4 and general procedure 4.

The various processes of the invention are described in more detail in the following schemes with the following general procedures:

Scheme 1
General procedure 1

In the scheme 1, R¹, R², R³ and R⁴ are as defined hereinabove.

Step 1: compound of formula XI

The compound of formula X, which preparation is disclosed herein in the part synthesis of intermediates (see Example A), and compound IX are reacted at room temperature in
the appropriate solvent (e.g. acetic acid). The crude product is isolated and purified by conventional methods.

**Step 2: compound of formula XII**
The compound of formula XI is dissolved in the appropriate solvent (e.g. dry THF) and cooled. The appropriate reducing agent is added (e.g. Lithium aluminum hydride).

**Step 3: compound of formula XIII**
The compound of formula XII is dissolved in the appropriate solvent (e.g. dichloromethane) and the appropriate oxidizing agent is added (e.g. Mangan(IV) oxid).

**Step 4: compound of formula II**
The compound XIII is reacted with (1-Diazo-2-oxo-propyl)-phosphonic acid dimethyl ester. The crude product is isolated and purified by conventional methods.

**Step 5: compound of formula Ia**
The compound of formula II is reacted with the compound of formula III with the appropriate catalysts (e.g. Triphenylphosphine, bis(triphenylphosphine)palladium(II) chloride and Copper(I) iodide). The crude product is isolated and purified by conventional methods.

Scheme 1 and general procedure 1 are further illustrated in the section examples herein.

**Scheme 2**
General procedure 2
In the scheme 2, \( R^1, R^2, R^3 \) and \( R^4 \) are as defined hereinabove.

**Step 1: compound of formula XVI**

The compound of formula XIV is reacted with a compound of formula XV (\( Z \) is preferably \( B(OH)_2 \)) with the appropriate catalyst (e.g. \([Cu(OH)TMEDA]_2Cl_2 (1.13 \text{ g, 2 mmol})\)).

**Step 2: compound of formula XVII**

The compound of formula XVI is reacted with the appropriate halogen \( X \) (e.g. Iodine in Iodic acid, acetic acid, and concentrated sulfuric acid in water with carbon tetrachloride) and stirred overnight. The crude product is isolated and purified by conventional methods.

**Step 3: compound of formula IV**

The compound of formula XVII is reacted with the compound of formula VI wherein \( X \) is halogen (e.g. iodomethane). The crude product is purified by conventional methods.
Step 4: compound of formula Ia

Solution 1: the compound of formula IV, which preparation is disclosed herein in the part synthesis of intermediates (see Example C) and the compound of formula V are mixed under inert gas (e.g. argon).

Solution 2: The appropriate catalyst mixture is prepared under inert gas (e.g. triphenylphosphine, bis(triphenylphosphine)-palladium(II)chloride, copper(I)iodide and triethyl amine in THF).

Solutions 1 and 2 are mixed under heating (e.g. 40°C) and stirred. The crude product is purified by conventional methods.

Scheme 2 and general procedure 2 are further illustrated in the section examples herein.

Scheme 3

General procedure 3

In the scheme 3, R¹, R², R³ and R⁴ are as defined hereinafore.

The compound of formula Ic is reacted with the compound of formula VI wherein X is halogen (e.g. iodomethane). The crude product is purified by conventional methods.

Scheme 3 and general procedure 3 are further illustrated in the section examples herein.

Scheme 4
General procedure 4

In the scheme 4, \( R^1, R^2, R^3 \) and \( R^4 \) are as defined hereinabove.

5 Step 1: compound of formula XX

A solution of the compound of formula XVIII and of the compound of formula XIX are reacted with the appropriate catalyst (e.g. 1-Ethoxyvinyltributyltin and Tetrakis(triphenylphosphine) Palladium in 130 ml of Toluene) The crude product is used directly in the next step.

10 Step 2: compound of formula XXI

A solution of the compound of formula XX (e.g. in pyridine) is added to Trichloroacetyl chloride. The product of formula XXI is obtained by conventional work up.

Step 3: compound of formula XXIII

A solution of the compound of formula XXI (e.g. in ethanol) is added to a solution of the compound of formula XII. The compound of formula XXIII is obtained by conventional work up.

Step 4: compound of formula XXIV

To a well stirred solution of the compound of formula XXIII (e.g. in Acetonitrile) are added Iodine and Cerium ammonium nitrate. The compound of formula XXIV is obtained by conventional work up.
Step 5: compound of formula XXV
To a solution of compound of formula XXIV (e.g. in dry THF) is added a solution of n-Butyllithium in THF. The compound of formula VI is then added (X is halogen). The product of formula XXV is obtained by conventional work up.

Step 6: compound of formula XXVI
To a suspension of N,O-Dimethylhydroxylamine ethyl ester (e.g. in dry methylene chloride) is added a solution of Trimethylaluminium (e.g. in Heptane). Then a solution of the compound of formula XXV is added (e.g. in dry methylene chloride). The product of formula XXVI is obtained by conventional work up.

Step 7: compound of formula XXVIII
A solution of sodium-bis(trimethylsilyl)amide (e.g. in THF) is added to the compound of formula XXVII (e.g. in dry THF). Then a solution of the compound of formula XXVI (e.g. in dry THF) is added. The product of formula XXVIII is obtained by conventional work up.

Step 8: compound of formula XXIX
To dry Methylene chloride is added Chloromethylene-dimethylimididium chloride. Then a solution of compound of formula XXVIII (e.g. in dry methylene chloride) is added. The product of formula XXVIII is obtained by conventional work up.

Step 9: compound of formula Ib
To Potassium tert-butylate (e.g. in THF and water is added a solution of the compound of formula XXIX (e.g. in THF). The desired product of formula Ib is obtained by conventional work up.

Scheme 4 and general procedure 4 are further illustrated in the section examples herein.

Scheme 5
General procedure 5

In the scheme 5, R¹, R², R³ and R⁴ are as defined hereinabove.

Step 1: compound of formula XI

The compound of formula XXX, which preparation is disclosed herein in the part synthesis of intermediates (see Example C), and compound IX are reacted at room temperature or higher temperature in the appropriate solvent (e.g. toluene). The crude product is concentrated and reacted with a compound of formula XXXI under hydrogen atmosphere in the presence of palladium to form a compound of formula XI which is isolated and purified by conventional methods.

Step 2: compound of formula XXXII

A solution of sodium-bis(trimethylsilyl)amide (e.g. in THF) is added to the compound of formula XXVII (e.g. in dry THF). Then a solution of the compound of formula XI (e.g. in dry THF) is added. The product of formula XXXII is obtained by conventional work up.
Step 3: compound of formula XXXIII

To dry methylene chloride is added chloromethylene-dimethylimidium chloride. Then a solution of compound of formula XXXII (e.g. in dry methylene chloride) is added. The product of formula XXXIII is obtained by conventional work up.

Step 4: compound of formula Ib

To Potassium tert-butylate (e.g. in THF and water is added a solution of the compound of formula XXXIII (e.g. in THF). The desired product of formula Ib is obtained by conventional work up.

Scheme 5 and general procedure 5 are further illustrated in the section examples herein.

Pharmaceutically acceptable salts of compounds of formulae I, Ia and Ib can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds.

The compounds of formulae I, Ia and Ib and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain. Treatable neurological disorders are for instance epilepsy, schizophrenia, anxiety, acute, traumatic or chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Huntington's chorea, ALS, multiple sclerosis, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, ethanol addiction, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain,
spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Other treatable indications are protection against liver damage, failure whether drug or disease induced, urinary incontinence, obesity, Fragile-X or Autism.

In addition, it is proposed that mGlu5 receptor antagonists protect against liver damage / failure whether drug or disease induced.

Storto, MariAnna; Battaglia, Giuseppe; Gradini, Roberto; Bruno, Valeria; Nicoletti, Ferdinando; Vairetti, Mariapia. Mouse hepatocytes lacking mGlu5 metabotropic glutamate receptors are less sensitive to hypoxic damage. European Journal of Pharmacology (2004), 497(1), 25-27.

Storto, MariAnna; Ngomba, Richard Teke; Battaglia, Giuseppe; Freitas, Isabel; Griffini, Patrizia; Richelmi, Plinio; Nicoletti, Ferdinando; Vairetti, Mariapia. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice. Journal of Hepatology (2003), 38(2), 179-187.

Storto, MariAnna; De Grazia, Ugo; Knopfel, Thomas; Canonico, Pier Luigi; Copani, Agata; Richelmi, Plinio; Nicoletti, Ferdinando; Vairetti, Mariapia. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Hepatology (Philadelphia) (2000), 31(3), 649-655.

The compounds of formula I, Ia and Ib and their pharmaceutically acceptable salts are especially useful as analgesics. Treatable kinds of pain include inflammatory pain such as arthritis and rheumatoid disease, vasculitis, neuropathic pain such as trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, hyperalgesia, severe chronic pain, post-operative pain and pain associated with various conditions like cancer, angina, renal or billiay colic, menstruation, migraine and gout.

The pharmacological activity of the compounds was tested using the following method:

For binding experiments, cDNA encoding human mGlu 5a receptor was transiently transfected into EBNA cells using a procedure described by Schlaeger and Christensen [Cytotechnology 15:1-13 (1998)]. Cell membrane homogenates were stored at -80°C until the day of assay where upon they were thawed and resuspended and polytronised in
15 mM Tris-HCl, 120 mM NaCl, 100 mM KCl, 25 mM CaCl₂, 25 mM MgCl₂ binding
buffer at pH 7.4 to a final assay concentration of 20 μg protein/well.

Saturation isotherms were determined by addition of twelve [³H]MPEP
concentrations (0.04-100 nM) to these membranes (in a total volume of 200 μl) for 1 h at
4°C. Competition experiments were performed with a fixed concentration of [³H]MPEP
(2nM) and IC₅₀ values of test compounds evaluated using 11 concentrations (0.3-
10,000nM). Incubations were performed for 1 h at 4°C.

At the end of the incubation, membranes were filtered onto unifilter (96-well white
microplate with bonded GF/C filter preincubated 1 h in 0.1% PEI in wash buffer, Packard
BioScience, Meriden, CT) with a Filtermate 96 harvester (Packard BioScience) and
washed 3 times with cold 50 mM Tris-HCl, pH 7.4 buffer. Nonspecific binding was
measured in the presence of 10 μM MPEP. The radioactivity on the filter was counted (3
min) on a Packard Top-count microplate scintillation counter with quenching correction
after addition of 45 μl of microscint 40 (Canberra Packard S.A., Zürich, Switzerland) and
shaking for 20 min.

For functional assays, [Ca²⁺]ᵢ measurements were performed as described
previously by Porter et al. [Br. J. Pharmacol. 128:13-20 (1999)] on recombinant human
mGlu 5a receptors in HEK-293 cells. The cells were dye loaded using Fluo™ 4-AM
(available from FLUKA, 0.2μM final concentration). [Ca²⁺]ᵢ measurements were
performed using a fluorometric imaging plate reader (FLIPR™, Molecular Devices
Corporation, La Jolla, CA, USA). Antagonist evaluation was performed following a 5 min
preincubation with the test compounds followed by the addition of a submaximal
addition of agonist.

The inhibition (antagonists) curves were fitted with a four parameter logistic
equation giving IC₅₀, and Hill coefficient using iterative non linear curve fitting software
(Xcel™ fit).

For binding experiments the Ki values of the compounds tested are given. The Ki
value is defined by the following formula:

\[ K_i = \frac{IC_{50}}{[1 + L / K_d]} \]

in which the IC₅₀ values are those concentrations of the compounds tested which cause
50% inhibition of the competing radioligand ([³H]MPEP). L is the concentration of
radioligand used in the binding experiment and the $K_d$ value of the radioligand is empirically determined for each batch of membranes prepared.

The compounds of the present invention are mGluR 5a receptor antagonists. The activities of compounds of formulae I, Ia and Ib as measured in the assay described above and as presented in the table hereafter are in the range of $K_i < 250$ nM.

<table>
<thead>
<tr>
<th>Example</th>
<th>$K_i$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>39</td>
</tr>
<tr>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>27</td>
<td>42</td>
</tr>
<tr>
<td>28</td>
<td>211</td>
</tr>
</tbody>
</table>

The compounds of formulae I, Ia and Ib and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.

However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I, Ia and Ib and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such as carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I,
but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.

The following examples are provided to further elucidate the invention:

**Example 1**

2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethyl]-pyridine

(prepared according to general procedure 3)

The title compound can be prepared according to general procedure 1 or general procedure 3. The preparation of the title compound according to general procedure 3 is described hereafter in example 1 and the preparation of the title compound according to general procedure 1 is described in example 3.

This compound was prepared according to the general procedure 3 described hereinabove.

2-chloro-4-[1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethyl]-pyridine (200 mg, 0.607 mmol) was dissolved in 10 mL THF and cooled to -75°C. Lithiumdiisopropylamide (0.45 ml, 0.91 mmol) was added and the mixture stirred for 15 min at -75°C. Iodomethane (0.05 ml, 0.85 mmol) was added and stirring was continued at -75 °C for 2
hrs. The reaction mixture was quenched with sat. NaHCO₃ solution and extracted with water and ethyl acetate. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethylacetate 90:10 -> 20:80 gradient) and by recrystallization from ethyl acetate. The desired compound was obtained as a white solid (40 mg, 19%), MS: m/e = 326.5 (M+H⁺).

Example 2

2-Chloro-4-[1-(2,4-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine

This compound was prepared according to the general procedure 1 described hereinabove.

Step 1: 1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazole-4-carboxylic acid ethyl ester

(Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester (5.5 g, 26 mmol) (Example A) and 2,4-Difluoroaniline (3.3 g, 26 mmol) were stirred at room temperature in acetic acid (45 ml) for 2 hrs. The reaction mixture was evaporated under vacuum at 40°C to obtain 10.3 g dark brown solid [(Z)-2-Acetylamino-3-(2, 4-difluoro-phenylamino)-but-2-enoic acid ethyl ester] [MS: m/e = 299.2 (M+H⁺)], which was refluxed over night at 145°C with fine powdered ammonium sulfate (0.17 g, 1 mmol) in hexamethyldisilazane (64 ml, 306 mmol). The reaction mixture was slowly cooled to 0-5°C. The precipitated solid was filtered and washed with n-hexane to obtain the desired compound as a light brown crystalline solid (1.76 g, 25%), MS: m/e = 281.1 (M+H⁺).

Step 2: 1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-methanol

1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazole-4-carboxylic acid ethyl ester (0.5 g, 2 mmol) was dissolved in 15 mL dry THF and cooled to 0°C. Lithium aluminum hydride (2.0 mL, 1M in THF, 2 mmol) was added dropwise and stirred for 45 min at 0°C. The reaction mixture was quenched with 76μl water, 76μl 15% sodium hydroxide and 230μl water. Sodium sulfate was added, stirred for 10 min, filtered and evaporated to dryness to obtain the desired compound as a white solid (0.39 g, 92%), MS: m/e = 239.2 (M+H⁺).

Step 3: 1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-carbaldehyde

[1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-methanol (0.38 g, 1.6 mmol) was dissolved in 35 ml dichloromethane. Manganese(IV) oxide (1.38 g, 16 mmol) was added and the reaction mixture stirred at reflux for 2 hrs. The suspension was filtered through a dicalite speed plus pad and washed with dichloromethane. The solvents were evaporated and the desired compound was obtained as a yellow oil (0.325 g, 86%), MS: m/e = 237.1 (M+H⁺).
Step 4: 1-(2,4-Difluoro-phenyl)-4-ethynyl-2,5-dimethyl-1H-imidazole
(1-Diazo-2-oxo-propyl)-phosphonic acid dimethyl ester (0.37 g, 2 mmol) was dissolved in 20 mL methanol. Potassium carbonate (0.38 g, 3 mmol) was added. A solution of 1-(2,4-Difluoro-phenyl)-2,5-dimethyl-1H-imidazole-4-carbaldehyde (0.32 g, 1 mmol) in 5 mL methanol was added drop wise at room temperature. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated. The residue was taken up in 15 mL water and extracted three times with ethyl acetate (15 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane/ethyl acetate 90:10 → 50:50 gradient) and the desired compound was obtained as a light yellow solid (0.165 g, 52%), MS: m/e = 233.1 (M+).

Step 5: 2-Chloro-4-[1-(2,4-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
2-Chloro-4-iodo-pyridine (0.21 g, 1 mmol) was dissolved in 10 mL of dry THF and 0.29 mL triethyl amine. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution. Triphenylphosphine (5 mg, 0.03 eq) and bis(triphenylphosphine) palladium(II) chloride (24 mg, 0.05 eq) were added and the reaction mixture was stirred at room temperature for 10 min. 1-(2,4-Difluoro-phenyl)-4-ethynyl-2,5-dimethyl-1H-imidazole (0.16 g, 1 mmol) and Copper(I) iodide (3 mg, 0.02 eq) were added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated. The residue was taken up in 10 mL water and extracted three times with ethyl acetate (10 mL each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (n-heptane/ethyl acetate 1:1) and recrystallized from diethyl ether. The desired product was obtained as a white solid (0.1 g, 42%), MS: m/e = 344.0 (M+).

Example 3

2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
(prepared according to general procedure 1)

The title compound, MS: m/e = 326.2 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester and 4-Fluoroaniline.

Example 4

2-Chloro-4-[1-(3,5-difluoro-phenyl)-2,5-methyl-1H-imidazol-4-ylethynyl]-pyridine
The title compound, MS: m/e = 344.0 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamo-ino-3-dimethylamino-but-2-enoic acid ethyl ester and 3,5-Difluoroaniline.

Example 5
2-Chloro-4-[1-(4-fluoro-2-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-y lethynyl]-pyridine
The title compound, MS: m/e = 340.0 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamo-ino-3-dimethylamino-but-2-enoic acid ethyl ester and 4-Fluoro-2-methylaniline.

Example 6
2-Chloro-4-[1-(4-fluoro-3-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-y lethynyl]-pyridine
The title compound, MS: m/e = 340.0 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamo-ino-3-dimethylamino-but-2-enoic acid ethyl ester and 4-Fluoro-3-methylaniline.

Example 7
2-Chloro-4-(2,5-dimethyl-1-p-tolyl-1H-imidazol-4-y lethynyl)-pyridine
This compound was prepared according to the general procedure 3 as described herein above. 2-Chloro-4-(2-methyl-1-p-tolyl-1H-imidazol-4-y lethynyl)-pyridine (220 mg, 0.71 mmol) was dissolved in 5 mL THF and cooled to -75°C. Lithiumdiisopropylamide (0.61 ml, 1.22 mmol) was added and the mixture stirred for 15 min at -75°C. Iodomethane (0.08 ml, 1.14 mmol) was added and stirring was continued at -75 °C for 2 hrs. The reaction mixture was quenched with sat. NaHCO₃ Solution and extracted with water and ethyl acetate. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethylacetate 90:10 -> 0:100 gradient) and by recrystallization from dichloromethane and diisopropylether. The desired compound was obtained as a light yellow solid (30 mg, 13%), MS: m/e = 322.3 (M+H+)..

Example 8
2-Chloro-4-[1-(3-chloro-4-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-y lethynyl]-pyridine
The title compound, MS: m/e = 356.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylaminobut-2-enoic acid ethyl ester and 3-Chloro-4-methylaniline.

Example 9

2-Chloro-4-[1-(3-fluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylythynyl]-pyridine
The title compound, MS: m/e = 356.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylaminobut-2-enoic acid ethyl ester and 2-Fluoro-p-anisidine.

Example 10

2-Chloro-4-[1-(4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylythynyl]-pyridine
The title compound, MS: m/e = 338.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylaminobut-2-enoic acid ethyl ester and p-Anisidine.

Example 11

2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylythynyl]-pyridine
The title compound, MS: m/e = 392.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylaminobut-2-enoic acid ethyl ester and 4-(Trifluoromethoxy)aniline.

Example 12

2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethoxy-phenyl)-1H-imidazol-4-ylythynyl]-pyridine
The title compound, MS: m/e = 392.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylaminobut-2-enoic acid ethyl ester and 3-(Trifluoromethoxy)aniline.

Example 13

2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazol-4-ylythynyl]-pyridine
This compound was prepared according to the general procedure 2 as described hereinabove.

Step 1: 2-Methyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole

2-Methylimidazole (1.0 g, 12 mmol) was dissolved in 35 mL THF. 4-(Trifluoromethyl)phenylboronic acid (2.66 g, 14 mmol) and [Cu(OH)TMEDA]_2Cl_2 (1.13 g, 2 mmol) were added. Oxygen was bubbled through the reaction mixture for 30 minutes and stirring was continued at room temperature overnight. The reaction mixture was filtered through a dicalite™ speed plus pad, washed with 80 ml THF and evaporated. The crude product was purified by flash chromatography on silica gel with ethyl acetate.

The desired compound was obtained as a light yellow solid (1.6 g, 58%), MS: m/e = 227.2 (M+H+).

Step 2: 4,5-Diiodo-2-methyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole

A mixture of 2-Methyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole (1.6 g, 7.1 mmol), iodine (2.15 g, 8.5 mmol), Iodric acid (0.75 g, 4.2 mmol), 25 ml acetic acid, 2.5 ml 30% sulfuric acid in water and 4 ml carbon tetrachloride was stirred overnight at 80°C. The reaction mixture was cooled to room temperature, decolorized with 5% NaHSO_3 Solution and basified to pH 9 with sodium hydroxide. Water was added and extracted two times with 50 ml ethyl acetate. The organic layers were washed with Brine, dried with sodium sulfate and evaporated. The crude product was recrystallized with little ethyl acetate and cyclohexane. The desired product was obtained as a light yellow solid (1.05 g, 31%). MS: m/e = 479.0 (M+).

Step 3: 4-Iodo-2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole

4,5-Diiodo-2-methyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole (1.0 g, 2.1 mmol) was dissolved in 15 ml THF and cooled to -75°C. n-Butyllithium (1.6M in Hexane) (1.60 ml, 2.5 mmol) was added and the mixture stirred for 60 min at -75°C. Iodomethane (0.19 ml, 3.0 mmol) was added and stirring was continued 30 min. at -75 °C and then 1h without dry ice bath. The reaction mixture was quenched with sat. NaHCO_3 Solution and extracted with water and ethyl acetate. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethylacetate 100:0 -> 60:40 gradient) and by recrystallization from little ethyl acetate and cyclohexane. The desired compound was obtained as a white solid (197 mg, 26%), MS: m/e = 367.0 (M+H^+).
Step 4: 2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine

Solution 1: 2-Chloro-4-trimethylsilanylethynyl-pyridine (144 mg, 0.69 mmol) (Example B) and 4-Iodo-2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazole (180 mg, 0.49 mmol) were dissolved in 3 ml dry THF. This mixture was evacuated and backfilled with argon several times to remove oxygen from the solution.

Solution 2: Triphenylphosphine (4 mg, < 0.1 mmol), bis(triphenylphosphine)-palladium(II)chloride (21 mg, < 0.1 mmol), copper(I)iodide (3 mg, < 0.1 mmol) and triethyl amine (0.1 ml, 0.71 mmol) were dissolved in 4 ml dry THF. This mixture was also evacuated and backfilled with argon several times to remove oxygen from the solution.

Solution 2 was heated to 40°C and solution 1 was added dropwise. The reaction mixture was heated to 60°C and tetrabutylammonium fluoride solution (1M in THF, 0.7 ml, 0.7 mmol) was added drop wise. The reaction was then stirred 2 hrs at 60°C. The residue was taken up in 15 ml water and extracted two times with ethyl acetate (15 ml each). The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (heptane/ethyl acetate 1:1) and recrystallized from little ethyl acetate and cadoxhexane. The desired product was obtained as a white solid (95 mg, 51%), MS: m/e = 376.3 (M+H+).

Example 14

2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine

The title compound, MS: m/e = 406.2 (M+H+), was prepared in accordance with the general method of example 13 (procedure 2) from 2-Methylimidazole and 3-Methyl-4-(trifluoromethoxy)phenylboronic acid (prepared from 4-Bromo-2-methyl-1-trifluoromethoxy-benzene).

Example 15

2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-methyl-pyridine

Step 1: 5-Methyl-2-(2-methyl-imidazol-1-yl)-pyridine

2-Methylimidazole (2.0 g, 24 mmol) and 2-Fluoro-5-methylpyridine (5.41 g, 49 mmol) were dissolved in 40 ml dimethyl formamide. Cesium carbonate (23.8 g, 73 mmol) was added and the reaction mixture was stirred at 100°C overnight. The reaction mixture was poured into 100 mL water and extracted three times with ethyl acetate (150 mL each). The combined organic extracts were dried with sodium sulfate, filtered and evaporated.
The desired compound was obtained as a brown oil (4.0 g, 95%), MS: m/e = 174.1 (M+H+).

Step 2: 2-[4-(2-Chloro-pyridin-4-y lethynyl)-2,5-dimethyl-imidazol-1-yl]-5-methyl-pyridine
The title compound, MS: m/e = 323.3 (M+H+), was prepared in accordance with the general method of example 13, step 2, 3 and 4 (procedure 2) from 5-Methyl-2-(2-methylimidazol-1-yl)-pyridine.

Example 16
2-Chloro-5-[4-(2-Chloro-pyridin-4-y lethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyridine
The title compound, MS: m/e = 344.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester and 5-Amino-2-chloropyridine.

Example 17
2-[4-(2-Chloro-pyridin-4-y lethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-4-trifluoromethyl-pyridine
The title compound, MS: m/e = 391.1 (M+H+), was prepared in accordance with the general method of example 15 from 2-Methylimidazole and 2-Chloro-6-methyl-4-(trifluoromethyl)-pyridine.

Example 18
2-[4-(2-Chloro-pyridin-4-y lethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyrazine
The title compound, MS: m/e = 310.2 (M+H+), was prepared in accordance with the general method of example 15, step 1 and example 12, step 4 from 5-Iodo-2,4-dimethyl-1H-imidazole (see synthesis of intermediates, example C) and 2-Chloropyrazine.

Example 19
2-Chloro-4-[1-(4-chloro-phenyl)-2,5-dimethyl-1H-imidazol-4-y lethynyl]-pyridine
The title compound, MS: m/e = 342.1 (M+H+), was prepared in accordance with the general method of example 13 (procedure 2) from 2-Methylimidazole and 4-Chlorophenylboronic acid.

Example 20
2-Chloro-4-[1-(3-chloro-2-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-yethynyl]-pyridine
The title compound, MS: m/e = 360.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester and 3-Chloro-2-fluoroaniline.

Example 21
2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-imidazol-4-yethynyl]-pyridine
The title compound, MS: m/e = 376.3 (M+H+), was prepared in accordance with the general method of example 13 (procedure 2) from 2-Methylimidazole and 3-(Trifluoromethyl)phenylboronic acid.

Example 22
2-Chloro-4-[1-(3-chloro-4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-yethynyl]-pyridine
The title compound, MS: m/e = 360.0 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester and 3-Chloro-4-fluoroaniline.

Example 23
2-[4-(2-Chloro-pyridin-4-yethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-pyridine
The title compound, MS: m/e = 323.3 (M+H+), was prepared in accordance with the general method of example 15 from 2-Methylimidazole and 2-Chloro-6-methyl-pyridine.

Example 24
2-[4-(2-Chloro-pyridin-4-yethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-(trifluoromethyl)-pyridine
The title compound, MS: m/e = 377.1 (M+H+), was prepared in accordance with the general method of example 15 from 2-Methylimidazole and 2-Chloro-6-trifluoromethylpyridine.

Example 25
2-Chloro-4-[2,5-dimethyl-1-(2-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-yethynyl]-pyridine
The title compound, was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester and 2-Methyl-4-(trifluoromethoxy)aniline.

Example 26
2-Chloro-4-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-ylethynyl]-pyridine
The title compound, was prepared in accordance with the general method of general procedure 4 and scheme 4.

Step 1: 1-(1-Ethoxy-vinyl)-4-fluoro-benzene
A solution of 10.0 g 4-Fluoro-iodobenzene, 21.1 g 1-Ethoxyvinyltributyltin and 2.6 g Tetrakis(triphenylphosphine)Palladium in 130 ml of Toluene was refluxed overnight under an argon atmosphere. The dark brown solution was filtered over filter aid and concentrated in vacuo. The crude dark brown oil (7.49 g) was directly used in the next step.

Step 2: 1,1,1-Trichloro-4-ethoxy-4-(4-fluoro-phenyl)-but-3-en-2-one
A solution of 7.49 g 1-(1-Ethoxy-vinyl)-4-Fluorobenzene in 3.6 mL of Pyridine was added at 0°C to 8.19 g of Trichloroacetyl chloride. The suspension was diluted with 15 ml of dry methylene chloride and stirred at room temperature overnight. The resulting dark brown suspension was concentrated in vacuo, filtered over a silicagel column with a 9:1 mixture of Heptane and Ethyl acetate as eluant. One obtains after concentration 28 g of a reddish brown oil which was repurified by chromatography on silicagel using a 19:1 mixture of Heptane and Ethyl acetate as eluant. The obtained brown oil (10.15 g) was directly used in the next step.

Step 3: 5-(4-Fluoro-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester
A solution of 10.15 g [1,1,1-Trichloro-4-ethoxy-4-(4-fluoro-phenyl)-but-3-en-2-one in 50 ml of Ethanol was added to dropwise to a solution of 2.1 ml of Methylhydrazine and 4.7 ml of 9N HCl/EtOH in 250 ml of Ethanol. The reaction mixture was stirred at reflux for 2 hrs. The yellow solution was allowed to cool and concentrated in vacuo. The residue was taken up in 200 ml of Methylene chloride. The organic phase was washed successively with 1N HCl solution and water. After drying over Magnesium sulfate and concentration, the crude product (8.56 g) was purified by chromatography over silica gel using a 2:1 mixture of Heptane and Ethyl acetate as eluant. The solvents were evaporated and the desired compound was obtained as a yellow oil (2.79 g, 35%), which solidified on standing, MS: m/e = 249.1 ([M+1]+).
Step 4: 5-(4-Fluoro-phenyl)-4-iodo-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 

To a well stirred solution of 2.79 g of 5-(4-Fluoro-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester in 100 ml of Acetonitrile were added 1.71 g of Iodine and 3.70 g of Cerium ammonium nitrate. The mixture was stirred for 3 h at 50°C. The red solution was then allowed to cool and was concentrated in vacuo. The residue was taken up in 200 ml of Ethyl acetate. The organic phase was successively washed with 5% Sodium bisulfite solution and brine. After drying over Magnesium sulfate and concentration, a beige solid 4.06 g (96%) was obtained which is sufficiently pure and was directly used in the next step. MS: m/e = 375.3 ([M+1]+).

Step 5: 5-(4-Fluoro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester 

To a -78°C solution of 4.06 g of 5-(4-Fluoro-phenyl)-4-iodo-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester in 80 mL of dry THF were added dropwise 8.13 ml of a 1.6 M solution of n-Butyllithium in THF maintaining the temperature below -70°C. The solution was stirred for 15 min at -75°C and 1.4 ml of Methyl iodide was added. The reaction mixture was stirred for 30 min at -75°C and allowed to warm up to room temperature. The mixture was worked up with Ethyl acetate and brine. The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product (3.15 g) was purified by chromatography on silica gel (Heptane/Ethyl acetate 2:1). The desired product was obtained as a yellow oil (1.00 g, 35%), which solidified on standing. MS: m/e = 263.1 ([M+1]+).

Step 6: 5-(4-Fluoro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid methoxymethyl-amide 

To a at 0°C cooled suspension of 0.54 g of N,O-Dimethylhydroxylamine ethyl ester in 10 mL of dry Methylene chloride were added dropwise 2.8 ml of a 2M solution of Trimethylaluminium in Heptane. The solution was stirred for 30 min at room temperature and then cooled to 0°C. Then a solution of 0.65 g 5-(4-Fluoro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester in 4 ml of dry Methylene chloride was added dropwise at 0°C. The solution was allowed to warm up to room temperature and stirred for 3 h. The reaction mixture was cooled to 0°C and 20 ml of water were added dropwise. The pH of the aqueous phase was adjusted to 7-8 with 1N Sodium hydroxide solution. The mixture was worked up with Methylene chloride and water. The combined organic extracts were dried with magnesium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (Heptane/Ethyl acetate 7:3). The desired product was obtained as a colorless oil (0.52 g, 68%), MS: m/e = 278.0 ([M+1]+).
Step 7: 2-(2-Chloro-pyridin-4-yl)-1-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-ethanone

To 10 ml of dry THF cooled to -65°C were added 1.35 ml of a 2M solution of Sodium-bis(trimethylsilyl)amide in THF. Then a solution of 0.32 g 2-Chloro-4-methyl pyridine in 1 ml of dry THF was added dropwise maintaining the temperature at -70°C for 30 min. Then a solution of 0.50 g of 5-(4-Fluoro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid methoxymethyl-amide in 5 ml of dry THF was added dropwise over a 10 min period maintaining the temperature below -65 °C. The solution was stirred for 2h at -60°C, and then allowed to warm up to 0°C and stirred for 20 min at this temperature. Then 0.31 ml of Acetic acid was added dropwise at -50°C and the solution was allowed to warm up to room temperature and stirred overnight. The mixture was concentrated in vacuo. The residue was taken up in Ethyl acetate. The organic phase was washed with saturated bicarbonate solution and brine, dried over magnesium sulfate, filtered and evaporated. The crude product (0.67 g, yellow oil) was purified by chromatography on silica gel (Heptane/Ethyl acetate 4:1). The desired product was obtained as a white solid (0.27 g, 70%), MS: m/e = 344.0 ([M+1]+).

Step 8: 3-Chloro-2-(2-chloro-pyridin-4-yl)-3-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-propenal

To 15 ml of dry Methylene chloride cooled to 0°C was added 0.34 ml of Chloromethylene-dimethylimidium chloride. Then a solution of 0.35 g 2-(2-Chloropyridin-4-yl)-1-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-ethanone in 6 ml of dry Methylene chloride was added at 0°C over a period of 5 min. The yellow suspension was stirred for 2.5 h at 0°C, and the diluted with 20 ml of Methylene chloride. The organic phase was washed with saturated bicarbonate solution and water, dried over magnesium sulfate, filtered and evaporated. The crude product (0.42 g, light yellow solid) was directly used in the next step, MS: m/e = 389.1 (M+).

Step 9: 2-Chloro-4-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-ylothynyl]-pyridine

To 11 ml of THF cooled to 0°C were added 0.26 g of Potassium tert-butylate and 20 μl of water.

Then a solution of 0.40 g 3-Chloro-2-(2-chloro-pyridin-4-yl)-3-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-yl]-propenal in 7 ml of THF was added at 0°. After stirring for 1 h at 5°C, 10 ml of 5% Bicarbonate solution were added and the aqueous phase was extracted twice with Ethyl acetate. The combined organic phases were washed with water
and brine, dried over magnesium sulfate, filtered and evaporated. The crude product (0.28 g, yellow oil) was purified by chromatography on silica gel (Heptane/Ethyl acetate 4:1). The desired product was obtained as a white solid (0.275 g, 82%), MS: m/e = 326.0 (M+).

Example 27

2-Chloro-4-[5-difluoromethyl-1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine

This compound was prepared according to the general procedure 3 described here inabove.

Step1: 5-(2-Chloro-pyridin-4-ylethynyl)-3-(4-fluoro-phenyl)-2-methyl-3H-imidazole-4-carbaldehyde:

2-chloro-4-[1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine (2.0 g, 6.42 mmol) was dissolved in 50 mL THF and cooled to -70°C. Lithiumdiisopropylamide 2M/THF (4.8 mL, 9.6 mmol) was added and the mixture stirred for 15 min at -70°C. Dimethylformamide (0.69 mL, 9.0 mmol) was added and stirring was continued at -70 °C for 3 hrs. The reaction mixture was quenched with sat. NaHCO₃ solution and extracted with water and ethyl acetate. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethylacetate 1:2). The desired compound was obtained as a yellow solid (220 mg, 10%), MS: m/e = 340.0 (M+H⁺).

Step2: 2-Chloro-4-[5-difluoromethyl-1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine:

To a solution of 100 mg (0.29 mmol) 5-(2-Chloro-pyridin-4-ylethynyl)-3-(4-fluoro-phenyl)-2-methyl-3H-imidazole-4-carbaldehyde in 3 ml of dry methylene chloride were added 125 mg (0.775 mmol) Diethylaminoisulfur trifluoride (DAST). The mixture was stirred at room temperature for 3d. The reaction mixture was quenched with sat. NaHCO₃ solution and extracted with water and methylene chloride. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethyl acetate 1:1). The desired compound was obtained as a light yellow solid (47 mg, 44%), MS: m/e = 362.1 (M+H⁺).

Example 28

[5-(2-Chloro-pyridin-4-ylethynyl)-3-(4-fluoro-phenyl)-2-methyl-3H-imidazol-4-yl]-methanol
To a solution of 100 mg (0.29 mmol) 5-(2-Chloro-pyridin-4-ylethynyl)-3-(4-fluorophenyl)-2-methyl-3H-imidazole-4-carbaldehyde (example 26) in 5 ml of methanol were added at 0°C 11 mg (0.29 mmol) of sodium borohydride, and the mixture was stirred for 1h at 0°C. The reaction mixture was quenched with sat. NaHCO₃ solution, and evaporated. The residue was extracted with water and ethyl acetate. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (heptane / ethyl acetate 1:1). The desired compound was obtained as a white solid (40 mg, 40%), MS: m/e = 342.1 (M+H⁺).

Example 29

2-Chloro-4-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine

This compound was prepared according to the general procedure 5 described hereinabove.

Step 1: 1-(4-Methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazole-4-carboxylic acid ethyl ester

Ethyl 2-Hydroxyimino-3-oxobutanoate (1.67 g, 10.5 mmol) (Example C), 3-trifluoromethyl-4-methoxyaniline (2.0 g, 10.5 mmol) and pyridinium p-toluenesulfonate (0.13 g, 0.52 mmol) were stirred at 75°C in toluene (15 ml) for 4 hrs. The reaction mixture was evaporated under vacuum at 40°C. The residue was dissolved in triethyl orthoacetate (14.3 ml, 78 mmol) and p-toluenesulfonic acid monohydrate (0.1 g, 0.52 mmol) and palladium on charcoal (0.6 g) were added. The reaction mixture was stirred for 4 hrs under hydrogen atmosphere. The dark suspension was filtered and evaporated to dryness. The crude product was recrystallized at 0°C from TBME and n-heptane. The desired product was obtained as a light brown solid (1.28 g, 36%), MS: m/e = 343.1 (M+H⁺).

Step 2: 2-(2-Chloro-pyridin-4-yl)-1-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-ethanone

1-(4-Methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazole-4-carboxylic acid ethyl ester (0.8 g, 2.3 mmol) and 2-chloro-4-methylpyridine (0.36 g, 2.8 mmol) were dissolved in 10 mL toluene. This solution was dropped to a cold (0°C) mixture of potassium bis(trimethylsilyl)amide (1.17 g, 5.84 mmol) in 15 mL toluene. The reaction mixture was stirred for 90 min. at 0°C. 0.4 mL acetic acid were added and the mixture extracted with water, saturated NaHCO₃-Solution and brine. The aqueous layer were washed with toluene (100 mL). The combined organic extracts were dried with sodium
sulfate and filtered. The solvent was evaporated and the crude product [(0.8 g, 81%), [MS: m/e = 424.5 (M+H+)]] was used without any further purification for the next step.

Step 3: 3-Chloro-2-(2-chloro-pyridin-4-yl)-3-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-propenal

A solution of 2-(2-Chloro-pyridin-4-yl)-1-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-ethanone (0.8 g, 1.9 mmol) in 8 mL dichloromethane was dropped to a cold (0°C) suspension of chloromethylendimethylmethyliminium chloride (0.6 g, 4.7 mmol) in 4 mL dichloromethane. The reaction mixture was stirred at 0°C for 1 hr. The reaction was diluted with 10 mL water and basified with saturated NaHCO₃-Solution to pH 8. The layers were separated and the aqueous layer was extracted with 100 mL dichloromethane. The organic layers were washed with water, combined and dried over magnesium sulfate. The solvent was evaporated and the crude product [(0.9 g, 100%), MS: m/e = 470.3 (M+H+)] was used without any further purification for the next step.

Step 4: 2-Chloro-4-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine

A solution of 3-Chloro-2-(2-chloro-pyridin-4-yl)-3-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yl]-propenal (0.9 g, 1.9 mmol) in 8 mL THF was dropped to a cold (0°C) suspension of potassium tert-butoxide (0.47 g, 4.2 mmol) in 4 mL THF and water (0.04 mL, 2.1 mmol). The light brown reaction mixture was stirred at 0°C for 1 hr. The reaction was extracted two times with ethyl acetate, saturated NaHCO₃-Solution, water and brine. The combined organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by chromatography on silica gel (n-heptane/ethyl acetate 90:10 -> 0:100) to obtained the desired product as a white solid (0.15 g, 19%), MS: m/e = 406.2 (M+H+).

Example 30
2-Chloro-4-[1-(3,5-difluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-yylethynyl]-pyridine
The title compound [MS: m/e = 373.9 (M+H+)], was prepared in accordance with the general method of example 29 (general procedure 5) from Ethyl 2-Hydroxyimino-3-oxobutanoate (Example C) and 3,5-Difluoro-4-methoxaniline (Example D).

Example 31
2-Chloro-4-[1-(4-methoxy-3-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
The title compound [MS: m/e = 421.9 (M+H+)], was prepared in accordance with the general method of example 29 (general procedure 5) from Ethyl 2-Hydroxyimino-3-oxobutanoate (Example C) and 4-Methoxy-3-trifluoromethoxyaniline (Example E).

Example 32
2-Chloro-4-[1-(3-methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
The title compound [MS: m/e = 421.9 (M+H+)], was prepared in accordance with the general method of example 29 (general procedure 5) from Ethyl 2-Hydroxyimino-3-oxobutanoate (Example C) and 3-Methoxy-4-trifluoromethoxyaniline (Example F).

Example 33
3-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-fluoro-pyridine
The title compound, MS: m/e = 327.0 (M+H+), was prepared in accordance with the general method of example 15 from 2-Methylimidazole and 3,5-difluoropyridine.

Example 34
4-{3-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-imidazol-1-yl]-5-fluoro-phenyl}-morpholine
A mixture of 2-Chloro-4-[1-(3,5-difluoro-phenyl)-2,5-methyl-1H-imidazol-4-ylethynyl]-pyridine (0.08 g, 0.23 mmol) (Example 4), morpholine (0.041 g, 0.46 mmol) and potassium carbonate (0.13 g, 0.92 mmol) in 1 mL DMSO was stirred at 100°C for 60 hrs. The reaction mixture was cooled and extracted two times with ethyl acetate and water. The organic layers were washed with brine, combined and dried over sodium sulfate. The solvent was evaporated and the crude product was purified by chromatography on silica gel (n-heptane/ethyl acetate 90:10 -> 30:70) and recrystallized from diisopropylether to obtained the desired product as a white solid (8.0 mg, 8%), MS: m/e = 411.2 (M+H+).

Example 35
2-Chloro-4-[1-(4-fluoro-2-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
The title compound, MS: m/e = 410.0 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino- but-2-enoic acid ethyl ester and 4-Fluoro-2-trifluoromethoxyaniline (Example G).

Example 36
2-Chloro-4-[1-(2-fluoro-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine
The title compound, MS: m/e = 410.1 (M+H+), was prepared in accordance with the general method of example 2 (procedure 1) from (Z)-2-Acetylamino-3-dimethylamino- but-2-enoic acid ethyl ester and 2-Fluoro-4-trifluoromethoxyaniline (Example H).

Example 37
The following examples can also be prepared as according to general procedure 1 or general procedure 5:
2-Chloro-4-[2,5-dimethyl-1-(4-methyl-3-trifluoromethyl-phenyl)-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethyl-phenyl)-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-5-trifluoromethyl-phenyl)-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-5-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-4-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3,5-dichloro-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3-fluoro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine; and
2-Chloro-4-[1-(3-fluoro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-yethyl]nyl]-pyridine.

Synthesis of Intermediates
Example A

(Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester

In this example of the compound X, R^2 and R^4 are both methyl. Nevertheless, it is understood that the person skilled in the art would be able to prepare other compounds of formula X, wherein R^2 and R^4 are other than methyl using the method of the following example:

Step 1: 4-[1-Dimethylamino-eth-(Z)-ylidene]-2-methyl-4H-oxazol-5-one

N-Acetylglucine (10.0 g, 85.4 mmol) and Phosphoroxychloride (19.6 ml, 213.5 mmol) were mixed and cooled to 5°C. N',N-Dimethylacetamide (19.7 ml, 213.5 mmol) was added drop-wise slowly during 30 min at 5-10°C (exothermic!). The reaction mixture was stirred at 45°C for 2 hrs and then cooled to room temperature. Dichloromethane (35 ml) was added and the mixture poured into 200 ml ice-water. The pH was adjusted to pH 8 with ammonium hydroxide and the mixture was extracted twice with 50 ml dichloromethane. The organic extracts were washed with 30 ml water, dried over magnesium sulfate, filtered and evaporated. The crude product was purified by column chromatography on silica gel (ethyl acetate) and the desired compound was obtained as a light brown solid (7.40 g, 51%), MS: m/e = 169.2 (M+H+).

Step 2: (Z)-2-Acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester

4-[1-Dimethylamino-eth-(Z)-ylidene]-2-methyl-4H-oxazol-5-one (7.4 g, 44.0 mmol) was dissolved in ethanol (50 ml) and sodium hydride (0.10 g, 4.4 mmol) was added at room temperature. The dark solution was refluxed for 1h. The solvent was evaporated and the crude product [MS: m/e = 215.5 (M+H+)] was used without any further purification for the next step.

Example B

5-Iodo-2,4-dimethyl-1H-imidazole

In this example of the compound XIX, R^2 is methyl, R^4 is methyl, and X is chloro. Nevertheless it is understood that the person skilled in the art would be able to prepare other compounds of formula XIX, wherein R^2 and R^4 are other than methyl, and X is other than chloro, using the method used for in the following example:

2,4-Dimethylimidazole (5.0 g, 52 mmol) was suspended in 100 ml Acetonitrile and N-Iodosuccinimide (14.0 g, 62.4 mmol) was added. The reaction mixture was stirred at reflux for 16 hours, then evaporated and decolorized with sat NaHSO_3 solution. Water was added and extracted twice with 100 ml ethyl acetate. The organic layers were washed with Brine, dried with sodium sulfate and evaporated. The crude product was
purified by chromatography on silica gel (dichloromethane/methanol 9:1). The desired product was obtained as a light brown solid (5.10 g, 44%), MS: m/e = 223.0 (M+H+).

Example C
Ethyl 2-Hydroxyimino-3-oxobutanoate

The title compound was prepared from ethyl acetoacetate in accordance with the literature reference of Robinson, Stanislawski & Mulholland, The Journal of Organic Chemistry, Volume 66, Number 12, 4148-4152 (2001).

Example D
3,5-Difluoro-4-methoxyaniline

The title compound was prepared from 2,6-difluorophenol in accordance with the literature reference of Qiu, Stevenson, O'Beirne and Silverman, J. Med. Chem. 1999, 42, 329-332.

Example E
4-Methoxy-3-trifluoromethoxyaniline

The title compound can be prepared in accordance with patent WO 2004007444.

Example F
3-Methoxy-4-trifluoromethoxyaniline

The title compound can be prepared in accordance with patent WO 9613492.

Example G
4-Fluoro-2-trifluoromethoxyaniline

The title compound can be prepared in accordance with patent EP 318704.

Example H
2-Fluoro-4-trifluoromethoxyaniline

The title compound can be prepared in accordance with patent EP 318704.

Preparation of the pharmaceutical compositions:

Example I

Tablets of the following composition are produced in a conventional manner:

mg/Tablet
Example II

Tablets of the following composition are produced in a conventional manner:

<table>
<thead>
<tr>
<th>Component</th>
<th>mg/Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active ingredient</td>
<td>200</td>
</tr>
<tr>
<td>Powdered. lactose</td>
<td>100</td>
</tr>
<tr>
<td>White corn starch</td>
<td>64</td>
</tr>
<tr>
<td>Polyvinylpyrrolidone</td>
<td>12</td>
</tr>
<tr>
<td>Na carboxymethylstarch</td>
<td>20</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>4</td>
</tr>
<tr>
<td>Tablet weight</td>
<td>400</td>
</tr>
</tbody>
</table>

Example III

Capsules of the following composition are produced:

<table>
<thead>
<tr>
<th>Component</th>
<th>mg/Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active ingredient</td>
<td>50</td>
</tr>
<tr>
<td>Crystalline. lactose</td>
<td>60</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>34</td>
</tr>
<tr>
<td>Talc</td>
<td>5</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>1</td>
</tr>
<tr>
<td>Capsule fill weight</td>
<td>150</td>
</tr>
</tbody>
</table>

The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.
CLAIMS:

1. A compound of the general formula

\[
\begin{array}{c}
  \text{A} \\
  \text{N} \\
  \text{E} \\
  \text{R}^2 \\
  \text{R}^4 \\
  \text{R}^3 \\
  \text{R}^1 \\
  \text{N} \\
  \text{E} \\
  \text{A} \\
\end{array}
\]

wherein

one of A or E is N and the other is C;

\( R^1 \) is halogen or cyano;
\( R^2 \) is C\(_1\)-C\(_6\) alkyl;
\( R^3 \) is aryl or heteroaryl, which is substituted or unsubstituted by:
one, two or three substituents, the substituent being halogen, C\(_1\)-C\(_6\) alkyl, C\(_1\)-C\(_6\) alkoxy, cycloalkyl, C\(_1\)-C\(_6\) haloalkyl, C\(_1\)-C\(_6\) haloalkoxy, cyano, or NR’R’”, or by
1-morpholinyl,
1-pyrrolidinyl, which is substituted or unsubstituted by (CH\(_2\))\(_{0,1}\)OR,
piperidinyl, which is substituted or unsubstituted by (CH\(_2\))\(_{0,1}\)OR,
1,1-dioxo-thiomorpholinyl or
piperazinyl, which is substituted or unsubstituted by C\(_1\)-C\(_6\) alkyl or (CH\(_2\))\(_{0,1}\)-
cycloalkyl,

wherein the aryl is an aromatic carbocyclic group consisting of one individual ring
or one or more fused rings in which at least one ring is aromatic in nature;

wherein the heteroaryl is an aromatic 5- or 6-membered ring containing one or
more heteroatoms, the heteroatom being nitrogen, oxygen, or sulfur;

\( R \) is hydrogen, C\(_1\)-C\(_6\) alkyl or (CH\(_2\))\(_{0,1}\)-cycloalkyl;

\( R', R'' \) are independently from each other hydrogen, C\(_1\)-C\(_6\) alkyl, (CH\(_2\))\(_{0,1}\)-cycloalkyl or
(CH\(_2\))\(_n\)OR;

\( n \) is 1 or 2;

\( R^4 \) is CH\(_2\)F, CF\(_3\), or C(O)H, CH\(_2\)R\(^5\) wherein \( R^5 \) is hydrogen, OH, C\(_1\)-C\(_6\)-alkyl or C\(_3\)-
C\(_{12}\)-cycloalkyl;

or pharmaceutically acceptable salts thereof.
2. The compound of claim 1, wherein the compound is of formula Ia:

\[
\begin{align*}
&\text{R}^1 &\text{R}^2 &\text{N} &\text{R}^3 &\text{R}^4 \\
\text{R}^5 &\text{R}^6 &\text{N} &\equiv &\text{R}^7 &\text{R}^8 \\
\text{R}^9 &\text{R}^{10} &\text{N} &\equiv &\text{R}^{11} &\text{R}^{12} \\
\end{align*}
\]

wherein \(R^1, R^2, R^3\) and \(R^4\) are as defined in claim 1; or pharmaceutically acceptable salts thereof.

3. The compound of claim 1, wherein the compound is of formula Ib:

\[
\begin{align*}
&\text{R}^1 &\text{R}^2 &\text{N} &\equiv &\text{R}^3 \\
\text{R}^4 &\text{R}^5 &\text{N} &\equiv &\text{R}^6 &\text{R}^7 \\
\text{R}^8 &\text{R}^9 &\text{N} &\equiv &\text{R}^{10} &\text{R}^{11} \\
\end{align*}
\]

wherein \(R^1, R^2, R^3\) and \(R^4\) are as defined in claim 1, and pharmaceutically acceptable salts thereof.

4. A compound according to any one of claims 2 or 3, wherein
\(R^1\) is halogen;
\(R^2\) is methyl or i-propyl;
\(R^3\) is phenyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl which is substituted or unsubstituted by one or more chloro, fluoro, \(C_1\)-\(C_6\) alkyl, \(C_1\)-\(C_6\) alkoxy, cyano, \(C_1\)-\(C_6\) haloalkyl, \(C_1\)-\(C_6\) haloalkoxy or cycloalkyl; and
\(R^4\) is CHF\(_2\); CH\(_2\)R\(^2\) wherein \(R^5\) is hydrogen, OH or \(C_1\)-\(C_6\)-alkyl;
or pharmaceutically acceptable salts thereof.

5. A compound of formula Ia according to claim 2, wherein \(R^3\) is unsubstituted or substituted heteroaryl, and wherein the substituents are chloro, fluoro, CF\(_3\), or \(C_1\)-\(C_6\) alkyl.

6. A compound of formula Ia according to claim 5 which is:
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-methyl-pyridine;
2-Chloro-5-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-4-trifluoromethyl-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-pyrazine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-methyl-pyridine;
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-6-(trifluoromethyl)-pyridine; or
3-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-1H-imidazol-1-yl]-5-fluoro-pyridine.

7. A compound of formula Ia according to claim 2, wherein R³ is aryl, substituted by one or more chloro, fluoro, CF₃, C₁-C₆ alkyl, C₁-C₆ alkoxy, CF₃O or 1-morpholinyl, wherein the aryl is an aromatic carbocyclic group consisting of one individual ring or one or more fused rings in which at least one ring is aromatic in nature.

8. A compound of formula Ia according to claim 7 which is:
2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(2,4-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3,5-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-fluoro-2-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-fluoro-3-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-(2,5-dimethyl-1-p-tolyl-1H-imidazol-4-ylethynyl)-pyridine;
2-Chloro-4-[1-(3-chloro-4-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-fluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-chloro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-2-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(2-methyl-4-trifluoromethoxy-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[5-difluoromethyl-1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine;
[5-(2-Chloro-pyridin-4-ylethynyl)-3-(4-fluoro-phenyl)-2-methyl-3H-imidazol-4-yl]-methanol;
2-Chloro-4-[1-(4-methoxy-3-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3,5-difluoro-4-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(4-methoxy-3-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
4-{3-[4-(2-Chloro-pyridin-4-ylethynyl)-2,5-dimethyl-imidazol-1-yl]-5-fluoro-phenyl}-morpholine;
2-Chloro-4-[1-(4-fluoro-2-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(2-fluoro-4-trifluoromethoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(4-methyl-3-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-4-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[2,5-dimethyl-1-(3-methyl-5-trifluoromethyl-phenyl)-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-5-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-methoxy-4-trifluoromethyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3,5-dichloro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-fluoro-5-methyl-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine;
2-Chloro-4-[1-(3-chloro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine; or
2-Chloro-4-[1-(3-fluoro-5-methoxy-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine.

9. A compound of formula Ib according to claim 3, wherein R³ is aryl, substituted by one or more fluoro, wherein the aryl is an aromatic carbocyclic group consisting of one individual ring or one or more fused rings in which at least one ring is aromatic in nature.

10. A compound of formula Ib according to claim 9, which is 2-Chloro-4-[5-(4-fluoro-phenyl)-1,4-dimethyl-1H-pyrazol-3-ylethynyl]-pyridine.

11. A process for preparing a compound of formula Ia according to claim 2, which process comprises reacting a compound of formula II

\[
\begin{align*}
\text{R}^2 \quad \text{N} \quad \text{C} \quad \text{C} \\
\text{R}^3 \quad \text{N} \quad \text{R}^4
\end{align*}
\]
with a compound of formula III

\[
\begin{align*}
\text{III) R}^1 & \quad \text{X} \\
\end{align*}
\]

in order to obtain the compound of formula Ia;
wherein \( R^1, R^2, R^3 \) and \( R^4 \) are as defined in claim 1 and \( X \) is halogen.

12. The process according to claim 11, further comprising converting the compounds obtained into pharmaceutically acceptable acid addition salts.

13. A process for preparing a compound of formula Ia as defined in claim 2, which process comprises reacting a compound of formula IV

\[
\begin{align*}
\text{IV) R}^2 & \quad \text{X} & \quad \text{R}^3 \quad \text{R}^4 \\
\end{align*}
\]

with a compound of formula V

\[
\begin{align*}
\text{V) R}^1 & \quad \text{X} \\
\end{align*}
\]

in order to obtain the compound of formula Ia;
wherein \( R^1, R^2, R^3 \) and \( R^4 \) are as defined in claim 1 and \( X \) is halogen.

14. The process according to claim 13, further comprising converting the compounds obtained into pharmaceutically acceptable acid addition salts.

15. A process for preparing a compound of formula Ia as defined in claim 2, which process comprises reacting a compound of formula Ic
with a compound of formula VI

$$R^4 X \quad (VI)$$

in order to obtain the compound of formula Ia;
wherein $R^1, R^2, R^3$ and $R^4$ are as defined in claim 1 and $X$ is halogen.

16. The process according to claim 15, further comprising converting the compounds obtained into pharmaceutically acceptable acid addition salts.

17. A process for preparing a compound of formula Ib as defined in claim 3, which process comprises reacting a compound of formula XXVI

$$XXVI$$

with a compound of formula XXVII

$$XXVII$$

in order to obtain a compound of formula XXVIII

$$XXVIII$$

and convert the compound of formula XXVIII into the compound of formula Ib;
wherein $R^1, R^2, R^3$ and $R^4$ are as defined in claim 1.
18. The process according to claim 17, further comprising converting the compounds obtained into pharmaceutically acceptable acid addition salts.

19. A medicament comprising one or more compounds as claimed in any one of claims 1 to 10 and a pharmaceutically acceptable excipient for treatment or prevention of an mGluR5 receptor mediated disorder, wherein the mGluR5 receptor mediated disorder is: an acute neurological disorder, a chronic neurological disorder, a cognitive disorder, a memory defect, acute or chronic pain, epilepsy, schizophrenia, an acute, traumatic or chronic degenerative process of the nervous system, Alzheimer's disease, senile dementia, Huntington's chorea, ALS, multiple sclerosis, dementia caused by AIDS, an eye injury, retinopathy, idiopathic parkinsonism, parkinsonism caused by medicaments, muscle spasms, convulsions, migraine, urinary incontinence, ethanol addiction, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, restricted brain function caused by bypass operations, transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycemia, drug or disease induced liver damage or failure, obesity, Fragile-X or Autism.

20. The medicament according to claim 19 for the treatment or prevention of an acute neurological disorder or chronic neurological disorder, for the treatment of chronic or acute pain, protection against drug or disease induced liver damage or failure, urinary incontinence, obesity, Fragile-X or Autism.

21. The medicament according to claim 20, wherein the acute or chronic neurological disorder is anxiety.

22. A compound according to any one of claims 1 to 10 or its pharmaceutically acceptable salt for use in treatment or prevention of a disease, wherein the disease is: an acute neurological disorder, a chronic neurological disorder, a cognitive disorder, a memory defect, acute or chronic pain, epilepsy, schizophrenia, an acute, traumatic or chronic degenerative process of the nervous system, Alzheimer's disease, senile dementia, Huntington's chorea, ALS, multiple sclerosis, dementia caused by AIDS, an eye injury,
retinopathy, idiopathic parkinsonism, parkinsonism caused by medicaments, muscle spasms, convulsions, migraine, urinary incontinence, ethanol addiction, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, restricted brain function caused by bypass operations, transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycemia, drug or disease induced liver damage or failure, obesity, Fragile-X or Autism.

23. Use of a compound according to any one of claims 1 to 10 or its pharmaceutically acceptable salt for the manufacture of a medicament for treatment and prevention of an acute neurological disorder or chronic neurological disorder, a cognitive disorder, a memory deficit, acute or chronic pain, epilepsy, schizophrenia, an acute, traumatic or chronic degenerative process of the nervous system, Alzheimer’s disease, senile dementia, Huntington’s chorea, ALS, multiple sclerosis, dementia caused by AIDS, an eye injury, retinopathy, idiopathic parkinsonism, parkinsonism caused by medicaments, muscle spasms, convulsions, migraine, urinary incontinence, ethanol addiction, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, restricted brain function caused by bypass operations, transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycemia, drug or disease induced liver damage or failure, obesity, Fragile-X or Autism.

24. The use according to claim 23 for the manufacture of a medicament for the treatment or prevention of an acute neurological disorder, a chronic neurological disorder, for the treatment of chronic or acute pain, for the protection against drug or disease induced liver damage or failure, or for urinary incontinence, obesity, Fragile-X or Autism.

25. Use of a compound according to any one of claims 1 to 10 or its pharmaceutically acceptable salt for treatment and prevention of an acute and chronic neurological disorder, a cognitive disorder, a memory deficit, acute and chronic pain, epilepsy, schizophrenia, an acute, traumatic or chronic degenerative process of the nervous system, Alzheimer’s disease, senile dementia, Huntington’s chorea, ALS, multiple sclerosis, dementia caused
by AIDS, an eye injury, retinopathy, idiopathic parkinsonism, parkinsonism caused by medicaments, muscle spasms, convulsions, migraine, urinary incontinence, ethanol addiction, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, restricted brain function caused by bypass operations, transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycemia, drug or disease induced liver damage or failure, obesity, Fragile-X or Autism.

26. The use according to claim 25 for the treatment and prevention of an acute or chronic neurological disorder, or for the treatment of chronic and acute pain, protection against drug or disease induced liver damage or failure, urinary incontinence, obesity, Fragile-X or Autism.